Moderna, well-known for its groundbreaking mRNA COVID-19 vaccine, posted an unexpected profit for Q3, surpassing analysts' estimates with strong vaccine sales and effective cost cutting measures. Despite this, concerns over vaccine demand slowdown and losses in market share have been highlighted. Legal battles loom with GSK suing Moderna for patent infringement in relation to COVID and RSV vaccines. The company's expanding horizons with an mRNA bird flu vaccine heavily backed by U.S. Government funding signal promising developments. Furthermore, the Canadian government's approval of the company's RSV vaccine for adults 60 and older and encouraging early trial results for mpox mRNA and solid tumour vaccines indicate robust progress. However, the patent dispute over mRNA breakthrough technology suggests potential hurdles. Despite a challenging outlook for 2025, as per an analyst, Moderna's strong financial results with significant revenue from covid vaccines, along with its efforts to innovate in the mRNA space with gene editing, maintain its prominence in the biotech sphere.
Moderna MRNA News Analytics from Wed, 07 Feb 2024 08:00:00 GMT to Sat, 09 Nov 2024 20:48:25 GMT -
Rating -1
- Innovation 8
- Information 6
- Rumor -7
